As described above, treatment with NMDAR antagonists, including ketamine and GluN2B NAMs, can induce the core symptoms of schizophrenia in healthy volunteers and exacerbate symptoms in patients [185–187]. This evidence concerns the gene GRIN2B and schizophrenia.